Project Grant K08CA283272
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$282K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
This Project Grant award of $112,230 from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program supports research at the University of Texas MD Anderson Cancer Center to investigate the role of gut microbiome dysbiosis in the development and progression of lung adenocarcinoma (LUAD), the most common type of non-small cell lung cancer. The research aims to determine how gut dysbiosis impacts immunomodulation and inflammation during LUAD development, and to...
This Project Grant award, identified as R01CA299862, is funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The award, totaling $606,839, supports research to investigate the role of microbiota amino acid metabolism in cancer. The key objectives of this 5-year project are to: 1) identify the microbes and their genes that actively deplete intestinal amino acids, and evaluate how they affect the tumor microenvironment and cancer progression;...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Stanford University to investigate how the human gut microbiome can be modulated to enhance immune responses against cancer, with a focus on improving the efficacy of cancer immunotherapy treatments. The $179,988 award, which runs from January 1, 2025 to December 31, 2026, aims to identify bacterial genes and functions that can boost the body's immune response to immune...
The National Cancer Institute (NCI), under the federal Cancer Research Manpower (CFDA 93.398) grant program, awarded a $304,906 Project Grant to The Trustees of Columbia University in the City of New York on August 23, 2024. The grant aims to advance the understanding of how bacteria, particularly E. coli, can selectively colonize tumor tissue and deliver cancer therapy. The project seeks to identify essential pathways for tumor colonization by bacteria and develop strategies to increase...
This $626,893 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Texas MD Anderson Cancer Center will fund research to study the role of bacterial-colonized microniches within tumors and their impact on intratumoral heterogeneity. The research aims to: 1) functionally map the cellular and metabolic features of these bacterial microniches within patient tumor tissues, 2) delineate the human cell types harboring intracellular...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
This federal Project Grant award of $636,222 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the University of Pittsburgh to investigate how immune checkpoint inhibitor-associated gut bacteria can modulate tumor immunity and enhance the efficacy of immune checkpoint inhibitor (ICI) therapy in melanoma. The key goals of the research are to: 1) Determine whether ICI-associated bacteria metabolize dietary tryptophan into aryl...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $678,399 to The University of Texas MD Anderson Cancer Center to conduct a prebiotic diet intervention study. The goal is to evaluate whether a prebiotic-enriched diet can enhance the gut microbiome and improve response to immune checkpoint inhibitor (ICI) therapy in patients with metastatic melanoma. The 5-year study will investigate the...
This Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), will fund a pilot study to evaluate the associations of pre- and post-chemotherapy and -radiotherapy gut microbiome profiles with breast cancer recurrence and mortality. The $175,000 award will support the use of shotgun metagenome sequencing on 110 post-treatment stool samples from the Vietnam Breast Cancer Study, as well as an investigation of the impact of...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $697,763 Project Grant to The University of Texas MD Anderson Cancer Center to conduct research on deciphering the critical determinants of enteric and tumor niche colonization by microbes, particularly Fusobacterium nucleatum (Fn), in colorectal cancer. The 5-year project aims to interrogate genetic factors enriched in Fn strains found in colorectal tumors versus the oral cavity, to understand how this microbe homes...